Summary & Overview
HCPCS G9108: Pancreatic Adenocarcinoma Disease Status, Staging Assessment
HCPCS Level II code G9108 represents an oncology disease-status assessment for pancreatic cancer limited to adenocarcinoma when the extent of disease is unknown, staging is in progress, or not listed, and is designated for use within a Medicare-approved demonstration project. This code matters nationally because it captures specialty oncology staging activity for a high-mortality cancer and is tied to demonstration-program reporting and reimbursement pathways that can influence care coordination and resource allocation for complex diagnostic workflows.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context for use of G9108, the typical setting where the service is delivered, and what to expect in high-level payer coverage posture. The publication also provides benchmarks and policy context where available, clarifies the scope of the service line for surgical and medical oncology teams, and highlights areas where implementation is specific to demonstration projects rather than routine claims practice.
The content focuses on national implications for coding, clinical staging workflows, and programmatic constraints tied to Medicare demonstration use. It is intended to help coding, billing, and oncology operations teams understand when G9108 applies and what kinds of documentation and staging activities are encapsulated by the code. Data not available in the input will be identified as such in detailed sections.
Billing Code Overview
HCPCS Level II code G9108 describes a service related to oncology disease status assessment for pancreatic cancer limited to adenocarcinoma where the extent of disease is unknown, staging is in progress, or not listed. The code is designated for use in a Medicare-approved demonstration project.
Service type: Oncology disease status evaluation / staging assessment
Typical site of service: Hospital outpatient department or oncology clinic where staging evaluations and multidisciplinary care are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with new-onset jaundice and weight loss is referred to a multidisciplinary oncology team after imaging suggests a pancreatic mass. The clinical workflow begins with diagnostic evaluation (contrast-enhanced CT and endoscopic ultrasound with biopsy) to confirm adenocarcinoma. Staging is incomplete at time of initial oncology consultation because further studies (PET/CT, MRI abdomen, surgical staging laparoscopy) are pending or results are pending. Under a Medicare-approved demonstration project, the oncology clinician documents disease status using billing code G9108 to indicate pancreatic adenocarcinoma with extent of disease unknown or staging in progress. Typical iterations of care include collection and review of pathology, ordering and scheduling of additional staging studies, multidisciplinary tumor board discussion, and formulation of an initial treatment plan (neoadjuvant therapy, surgical exploration, or palliative management) once staging is finalized. Services are typically delivered in an outpatient oncology clinic, academic cancer center, or hospital outpatient department as part of coordinated cancer care and clinical demonstration reporting requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Default when no modifier applies to the service |